Including measurements of serum prostate-specific antigens (PSA/KLK3) in the diagnosis of prostate cancer has led to a significant increase in the detection of early-stage PCa (Gleason < 6) [6–10]. The gene discussed is KLK3; the disease is posterior cortical atrophy.